Celiac Disease is the inability for the body to process gluten (part of some grains).
Lymphoma can develop in 15% of those with this condition. Enteropathy-type intestinal T cell lymphoma is the most common form.
Resources
Celiac Information http://www.celiac.com/
Medical Information from the NE Journal of Medicine
Books
Living With Lymphoma by Elizabeth Adler, Ph.D., Oct. 2005
Kids With Celiac Disease : A Family Guide to Raising Happy, Healthy, Gluten-Free Kids -- by Danna Korn; Available from Amazon in Paperback
Coping With Celiac, The Great Masquerader -- by Aileen M. Bennett; Available from Amazon in Paperback
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...